🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Fostering Data Sharing

Search Papers Authors Institutions Grants FAIR About

TheSindex

Fostering Data Sharing

Empowering the data sharing that empowers science — an open, citation-grounded index for datasets.

Product

Search
API
Explore
Rankings

Resources

Methodology
Data Sources
Documentation
Press

Organization

About
Team
Wikidata

© 2026 theSindex. All rights reserved.

Home
Authors
Katherine Odem‐Davis

Katherine Odem‐Davis

ORCID: 0000-0002-9779-2571

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 8 papers. Top paper: “Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials”.

Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials

The Lancet Respiratory Medicine(2022)10.1016/s2213-2600(22)00434-9

N/A

3.9DataRank · unranked

127 citations

Félix Ratjen, Renee Russell, Scott H. Donaldson, Kristin A. Riekert, Gregory S. Sawicki +91 more

Willingness of people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor (ETI) to participate in randomized modulator and inhaled antimicrobial clinical trials

Journal of Cystic Fibrosis(2023)10.1016/j.jcf.2023.04.007

N/A

0.347DataRank · unranked

5 citations

Edith T. Zemanick, Michael W. Konstan, Clement L. Ren, Katherine Odem‐Davis, I. Emerman +3 more

Characterizing CFTR modulated sweat chloride response across the cf population: Initial results from the CHEC-SC study

Journal of Cystic Fibrosis(2022)10.1016/j.jcf.2022.07.008

N/A

0DataRank · unranked

8 citations

Edith T. Zemanick, Katherine Odem‐Davis, Donald R. VanDevanter, Mark N. Warden, Steven M. Rowe +4 more

Adjunctive Systemic Corticosteroids for Pulmonary Exacerbations of Cystic Fibrosis

Annals of the American Thoracic Society(2023)10.1513/annalsats.202308-673oc

N/A

0DataRank · unranked

18 citations

Sonya L. Heltshe, Katherine Odem‐Davis, Natalie E. West, Don B. Sanders, B. Fogarty +4 more

Impact of lumacaftor/ivacaftor and tezacaftor/ivacaftor on treatment response in pulmonary exacerbations of F508del/F508del cystic fibrosis

Journal of Cystic Fibrosis(2023)10.1016/j.jcf.2023.06.012

N/A

0DataRank · unranked

10 citations

Sonya L. Heltshe, Katherine Odem‐Davis, Natalie E. West, Don B. Sanders, B. Fogarty +4 more

A randomized-controlled pilot study on the effects of naproxen for the treatment of bleeding and spotting among new Copper T 380A IUD users

Research Square(2020)10.21203/rs.3.rs-45458/v1

N/A

0DataRank · unranked

0 citations

C. Holly A. Andrilla, Katherine Odem‐Davis, Emily M. Godfrey

Heterogeneity of CFTR modulator-induced sweat chloride concentrations in people with cystic fibrosis

Journal of Cystic Fibrosis(2024)10.1016/j.jcf.2024.02.001

N/A

0DataRank · unranked

26 citations

I. Emerman, Morgan McCreary, N. Mayer-Hamblett, Mark N. Warden, Katherine Odem‐Davis +5 more

Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: Rationale and design of the CHEC-SC study

Journal of Cystic Fibrosis(2021)10.1016/j.jcf.2021.01.011

N/A

0DataRank · unranked

24 citations

Michael W. Konstan, Donald R. VanDevanter, Steven M. Rowe, JP Clancy, Katherine Odem‐Davis +3 more